 "Pfizer to acquire oncology specialist Medivation for $ 14 bn")
Pfizer Limited (India) today informed the stock exchange that it has entered into an agreement with AstraZeneca AB, Sweden, to acquire the brand Neksium in India for a value of Rs 75 crore. The transaction is subject to completion of requisite clearances, a press release issued by the company said.
Neksium was launched in India in the year 2006 and has developed strong equity with prescribers as a leading, high quality product in the Anti-Peptic Ulcerant space.
Neksium, with the active ingredient Esomeprazole belongs to a family of pharmaceutical preparations called Proton Pump Inhibitors (PPI) that are used
Neksium was launched in India in the year 2006 and has developed strong equity with prescribers as a leading, high quality product in the Anti-Peptic Ulcerant space.
Neksium, with the active ingredient Esomeprazole belongs to a family of pharmaceutical preparations called Proton Pump Inhibitors (PPI) that are used
